LMAT Valuation

LeMaitre Vascular Inc

Add to Watchlist

Advanced Chart

96.450

-0.26(-0.269%)1D

Overview
Forecast
Valuation
Earnings

LMAT Relative Valuation

LMAT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LMAT is overvalued; if below, it's undervalued.

Historical Valuation

LeMaitre Vascular Inc (LMAT) is now in the Undervalued zone, suggesting that its current forward PE ratio of 39.50 is considered Undervalued compared with the five-year average of 39.80. The fair price of LeMaitre Vascular Inc (LMAT) is between 113.10 to 134.49 according to relative valuation methord. Compared to the current price of 96.45 USD , LeMaitre Vascular Inc is Undervalued By 14.72%.

Relative Value

Fair Zone

113.10-134.49

Current Price：96.45

14.72%

Undervalued

39.50

Trailing

Forward

26.00

EV/EBITDA

LeMaitre Vascular Inc. (LMAT) has a current EV/EBITDA of 26.00. The 5-year average EV/EBITDA is 23.79. The thresholds are as follows: Strongly Undervalued below 16.53, Undervalued between 16.53 and 20.16, Fairly Valued between 27.43 and 20.16, Overvalued between 27.43 and 31.06, and Strongly Overvalued above 31.06. The current Forward EV/EBITDA of 26.00 falls within the Historic Trend Line -Fairly Valued range.

31.37

EV/EBIT

LeMaitre Vascular Inc. (LMAT) has a current EV/EBIT of 31.37. The 5-year average EV/EBIT is 30.25. The thresholds are as follows: Strongly Undervalued below 21.43, Undervalued between 21.43 and 25.84, Fairly Valued between 34.66 and 25.84, Overvalued between 34.66 and 39.07, and Strongly Overvalued above 39.07. The current Forward EV/EBIT of 31.37 falls within the Historic Trend Line -Fairly Valued range.

8.36

LeMaitre Vascular Inc. (LMAT) has a current PS of 8.36. The 5-year average PS is 6.83. The thresholds are as follows: Strongly Undervalued below 4.36, Undervalued between 4.36 and 5.59, Fairly Valued between 8.06 and 5.59, Overvalued between 8.06 and 9.29, and Strongly Overvalued above 9.29. The current Forward PS of 8.36 falls within the Overvalued range.

37.14

P/OCF

LeMaitre Vascular Inc. (LMAT) has a current P/OCF of 37.14. The 5-year average P/OCF is 41.62. The thresholds are as follows: Strongly Undervalued below 14.56, Undervalued between 14.56 and 28.09, Fairly Valued between 55.15 and 28.09, Overvalued between 55.15 and 68.68, and Strongly Overvalued above 68.68. The current Forward P/OCF of 37.14 falls within the Historic Trend Line -Fairly Valued range.

35.84

P/FCF

LeMaitre Vascular Inc. (LMAT) has a current P/FCF of 35.84. The 5-year average P/FCF is 37.15. The thresholds are as follows: Strongly Undervalued below 27.53, Undervalued between 27.53 and 32.34, Fairly Valued between 41.96 and 32.34, Overvalued between 41.96 and 46.77, and Strongly Overvalued above 46.77. The current Forward P/FCF of 35.84 falls within the Historic Trend Line -Fairly Valued range.

LeMaitre Vascular Inc (LMAT) has a current Price-to-Book (P/B) ratio of 5.98. Compared to its 3-year average P/B ratio of 5.07 , the current P/B ratio is approximately 17.97% higher. Relative to its 5-year average P/B ratio of 4.99, the current P/B ratio is about 19.94% higher. LeMaitre Vascular Inc (LMAT) has a Forward Free Cash Flow (FCF) yield of approximately 2.39%. Compared to its 3-year average FCF yield of 1.89%, the current FCF yield is approximately 26.59% lower. Relative to its 5-year average FCF yield of 2.39% , the current FCF yield is about -0.20% lower.

5.98

P/B

Median3y

5.07

Median5y

4.99

2.39

FCF Yield

Median3y

1.89

Median5y

2.39

Competitors Valuation Multiple

The average P/S ratio for LMAT's competitors is 4.31, providing a benchmark for relative valuation. LeMaitre Vascular Inc Corp (LMAT) exhibits a P/S ratio of 8.36, which is 93.88% above the industry average. Given its robust revenue growth of 15.01%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LMAT.O

LeMaitre Vascular Inc

Procept Biorobotics Corp

Alphatec Holdings Inc

Performance Decomposition

Market capitalization of LMAT increased by 6.82% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 55.85M to 64.23M.

The secondary factor is the Margin Expansion, contributed 1.32%to the performance.

Overall, the performance of LMAT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

15.01%

55.85M → 64.23M

Revenue Growth

1.32%

21.17 → 21.45

Margin Expansion

-9.51%

51.69 → 46.78

P/E Change

6.82%